Combination targeted therapy for advanced colorectal cancer with RAS mutations
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of two targeted drugs (tunlametinib and fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and who have already tried at least two other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need to have advanced colorectal cancer that has gotten worse after at least two previous treatments.
- Your cancer must have a specific gene change called a RAS mutation.
- You must be able to take pills by mouth and be generally mobile (able to do light activities).
- You need to have at least one tumor that can be measured on a scan.
- Your overall health must be fairly good, with normal blood counts, liver, kidney, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with advanced pancreatic or colorectal cancer that has a specific genetic change called a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a combination of drugs for people with advanced lung cancer that has a specific genetic change called KRAS. The treatment aims to shrink tumors or slow their growth after standard treatments have stopped working.
This trial tests a combination of two newer drugs plus chemotherapy as the first treatment for people with advanced colorectal cancer that has a RAS or BRAF gene change. The goal is to see if this combination helps shrink tumors and slow the cancer.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
Hear when a new CRC, Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.